Tumor Immunology Weekly News, January 20, 2020
Updated: Feb 1
Submissions open Jan 21 for SITC 2020 Fellowships, including the SITC-Genentech Women in Cancer Immunotherapy Fellowship.
Scientists at Boston University develop mesenchyme-free intestinal organoids from human iPSCs.
Image from CReM.
Intestine-chip populated with organoids performs better than organoids alone in preclinical testing.
Image by Emulate Inc.
Osteopontin-responsive Lgr5-CD44+ cells could be new targets for gastroesophageal cancer, according to Cornell study.
Image by the Nitikin Lab sourced from Cornell News.
New Science article showed selective ablation of PD-1 in myeloid cells was just as effective at limiting tumor growth as global deletion of PD-1.
Image sourced from Wikipedia.
New Organoid Research Facilities
WFORCE is a new organoid research center at the Wake Forest School of Medicine - focusing on personalized medicine, rare tumors and adaptive immunity.